Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

PURPOSE. To evaluate the maximum tolerated regimen (MTR), dose-limiting toxicities, and pharmacokinetics of pazopanib, an oral small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, in combination with paclitaxel....

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Tan, Antoinette R., Dowlati, Afshin, Jones, Suzanne F., Infante, Jeffrey R., Nishioka, Jennifer, Fang, Lei, Hodge, Jeffrey P., Gainer, Shelby D., Arumugham, Thangam, Suttle, A. Benjamin, Dar, Mohammed M., Lager, Joanne J., Burris, Howard A.
Format: Artigo
Sprog:Inglês
Udgivet: AlphaMed Press 2010
Fag:
Clinical Pharmacology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227920/
https://ncbi.nlm.nih.gov/pubmed/21147873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0095
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker